Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of end-stage renal disease and slow the progression of nephropathy, but they do not appear to decrease all-cause or cardiovascular mortality in people with Type 2 diabetes and proteinuria. 31407377 2020
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation disease BEFREE This meta-analysis suggested that I/D polymorphism of ACE can markedly increase the incidence of diabetes-related end-stage renal disease, especially in Asian populations. 30840289 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation disease BEFREE The C allele in rs5186 in AGTR1 was associated with higher rates of death and major cardiovascular events in a meta-analysis of EA and AfAn patients with end-stage kidney disease.SNPs in ACE were associated with SCD. 29982608 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE Angiotensin-converting enzyme inhibitors can remarkably delay the development of ESRD. 30128941 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation disease BEFREE Compared with DPP4i nonusers, DPP4i users had a lower risk of ESRD (hazard ratio, 0.81; 95% CI, 0.70-0.94; P=.04) and all-cause mortality (hazard ratio, 0.28; 95% CI, 0.23-0.34; P<.001) after adjustments for CKD, advanced CKD, and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use. 30343892 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE This meta-analysis aims to assess the benefits of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) supplemented with <italic>Rheum officinale</italic> for delaying the progression of chronic renal failure. 29208203 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (compared to other antihypertensive agents) was associated with a lower risk for eGFR <45 mL/min/1.73m², HR 0.64 (95% confidence interval [CI] 0.45-0.9), P = .01, and also less ESRD; HR 0.03 (95% CI 0.001-0.20), P = .004. 29498216 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 AlteredExpression disease BEFREE Additionally, BPS reduced the levels of MDA while increasing the levels of SOD, ACE activity, and AT1 expression in the renal tissues of CRF rats. 30078019 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation disease BEFREE For renal outcomes, ARBs significantly reduced the risk of ESRD by 23% (odds ratio 0.77, 95%CI 0.65-0.92), while ACE inhibitors were not associated with a decreased risk of ESRD (0.69, 0.43-1.10). 29794446 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE The association between the use of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) and mortality in end-stage renal disease (ESRD) patients lacks sufficient evidence. 29808610 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE End-stage renal disease and adherence to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among patients with diabetes. 28177196 2017
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE <b>Objective</b> To examine long term cardiorenal outcomes associated with increased concentrations of creatinine after the start of angiotensin converting enzyme inhibitor/angiotensin receptor blocker treatment.<b>Design</b> Population based cohort study using electronic health records from the Clinical Practice Research Datalink and Hospital Episode Statistics.<b>Setting</b> UK primary care, 1997-2014.<b>Participants</b> Patients starting treatment with angiotensin converting enzyme inhibitors or angiotensin receptor blockers (n=122 363).<b>Main outcome measures</b> Poisson regression was used to compare rates of end stage renal disease, myocardial infarction, heart failure, and death among patients with creatinine increases of 30% or more after starting treatment against those without such increases, and for each 10% increase in creatinine. 28279964 2017
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation disease BEFREE Our study sought to examine whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin type 1 receptor blockers (ARBs) could reduce the frequencies of cardiovascular and cerebrovascular events in patients receiving hemodialysis using the medication possession ratio (MPR) method of analysis.This retrospective cohort study identified cases of ESRD with dialysis from the National Health Insurance Research Database between 1999 and 2006, and used Cox-regression methods to evaluate risk of poor outcomes. 28353612 2017
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation disease BEFREE It is concluded that ACE-DD genotype may be a risk factor for the causation and development of chronic kidney failure among hypertensive patients. 27050505 2016
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE Angiotensin converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) have been shown to significantly delay the progression of chronic kidney disease and the onset of ESRD. 26995302 2016
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation disease BEFREE The DD genotype of the ACE I/D variation may be associated with more elevated blood pressure and HbA1c, and therefore may predict the development, progression and severity of DN-ESRD in Chinese patients with T2DM undergoing hemodialysis. 27633502 2016
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation disease BEFREE Significant associations were observed between ACE I/D and G2350A polymorphisms and ESRD. 23477970 2015
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation disease BEFREE The findings of this study indicate that I/D polymorphisms of the ACE gene are a useful marker and are likely to play a major role in determining genetic susceptibility to ESRD in the Malaysian population. 21421653 2015
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE Although angiotensin-converting enzyme inhibition is effective in Alport syndrome patients for slowing progression to end-stage renal disease, it is neither a cure nor an adequate long-term protector. 24988067 2014
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation disease BEFREE Thirteen articles were identified for the analysis of the association between ACE I/D gene polymorphism and ESRD risk in IgAN patients. 23060471 2013
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE The evidence for a beneficial renoprotective effect of renin-angiotensin-aldosterone system (RAAS) blockade by angiotensin-converting enzyme (ACE) inhibition and/or angiotensin receptor blockers (ARBs) is well established in AS and recent evidence has shown that it can significantly delay the time to onset of renal replacement therapy and ESKD. 22903660 2013
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE The estimation of relative mAb 1G12 binding to blood ACE detects a subpopulation of ESRD patients with conformationally changed ACE, which activity is less suppressible by ACE inhibitors. 23166630 2012
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation disease BEFREE Twelve studies reporting the relation between ACE I/D gene polymorphism and ESRD risk in DN patients were identified. 22385293 2012
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE 20 patients on angiotensin 1-converting enzyme inhibitor/angiotensin receptor antagonist (ACEI/ATRA) therapy were then compared with another 20 patients not treated with ACEI /ATRA to determine their renal outcome in response to ACEI/ATRA therapy and whether their genetic profile of ACE gene could play a role in determining their outcome to ACEI /ATRA therapy and progression to end-stage renal failure (ESRF). 22173253 2011
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE Conventional management consists of pain relief with analgesic drugs, nephroprotection (angiotensin converting enzyme inhibitors and angiotensin receptors blockers) and antiarrhythmic agents, whereas dialysis or renal transplantation are available for patients experiencing end-stage renal failure. 21092187 2010